If you have been prescribed TYMLOS® (abaloparatide) but are unable to afford it, Radius Assist may be able to help.
What is Radius Assist?
The Radius Assist Patient Assistance Program (“Radius Assist”) provides TYMLOS (abaloparatide) injection therapy at no cost to qualified patients in need.
To qualify, patients must meet the eligibility criteria and, along with their healthcare provider, submit all required documentation.
If a patient is accepted into the program, they will receive up to 3 months of medication per shipment, and up to 18 months of therapy. Acceptance into the program is valid for the current calendar year and with a valid prescription (subject to continued eligibility) and until the patient has reached a total of 18 months of therapy provided by Radius Assist.*
Who is Eligible for Radius Assist?
To be eligible for Radius Assist, patients should:
- have an FDA-approved, on-label diagnosis for TYMLOS (abaloparatide) injection;
- be legal residents of the contiguous United States, Alaska, or Hawaii; and
- have an annual household income of <300% Federal Poverty Level (FPL). Reference the chart below which shows gross annual income limits associated with Radius Assist.
Additional eligibility criteria vary based on the coverage of the patient.
To be eligible for Radius Assist as a Medicare beneficiaries, patients must not:
- be enrolled in Medicaid, Tricare, Veterans Health Administration, or Indian Health Service benefit programs;
- be eligible for full Low-Income Subsidy (LIS) from the Social Security Administration; and
- Patients in NY, PA, or WI must not be eligible for the State Pharmacy Assistance Programs
To be eligible for Radius Assist as a commercially insured patient:
- Patient must have neither insurance coverage for nor access to other coverage for TYMLOS.
2021 Gross Annual Income Limits Associated with Radius Assist
|Number of Persons in Household||Continental United States||Alaska||Hawaii|
How to Apply for Assistance
Prior to an application being completed, patients should call 1-866-896-5674 to complete an eligibility prescreening. The purpose of the prescreening is to help the patient understand if she may be eligible for Radius Assist by discussing the eligibility criteria including income verification. For applicants who do not meet the eligibility requirements, additional information on alternative options may be provided.
Note: A healthcare professional or an office representative may conduct a prescreening call on behalf of his/her patient.
If the patient meets the requirements based on the prescreening, an application prepopulated with demographic information will be mailed to her for review and signature. The prescriber must complete section 6 and 7 of the application as well. Both sections are required for an application to be considered complete.
Although a phone pre-screening is not a required step in the application process, we strongly encourage the use of this tool as it streamlines the patient application and decision processes. If the patient chooses not to complete a prescreening, they may download an application from the link below. Directions on how to submit are stated on page 1 of the application.
To submit, follow the instructions on page 1 of the application.
Once the application is submitted, the healthcare professional will receive a confirmation fax when Radius Assist is in receipt of the application. If information is missing, the Radius Assist team will reach out to the healthcare professional and/or the patient to obtain this. As a reminder, all information is required in order for Radius Assist to make a determination on eligibility.
If the application is approved, the healthcare professional will receive notification via fax and the patient will be notified via mail. The patient will then be contacted by the specialty pharmacy providing medication for Radius Assist patients, Nufactor, Inc., to coordinate medication shipment.
*Patients can receive up to, but not exceeding, 18 months of total TYMLOS therapy from Radius Assist. Radius Assist will discontinue providing therapy once the patient’s cumulative lifetime use of TYMLOS and/or other parathyroid hormone analogs (e.g., teriparatide) has reached 24 months. Cumulative use of TYMLOS and parathyroid hormone analogs (e.g., teriparatide) for more than 2 years during a patient’s lifetime is not recommended.